Tue, Jul 13, 2021
Kroll recently hosted a webcast series that brought together our leading experts and industry leaders to share insights on trends, valuation, technology, intellectual property (IP), risk and regulation in the life sciences industry. Please see below for more details on each session and a link to the event replays.
As big pharma and biotech conglomerates continue to seek growth following the COVID-19 pandemic, our experts provide insights on what will shape the future of the life sciences industry and dissect the key drivers of M&A activity.
Key Insights
Panelists
Purchase accounting valuation in the biotechnology industry can be particularly challenging. Understanding the intricacies of biotechnology valuation and having command best practices is key to successfully navigating the valuation process for all stakeholders. Duff & Phelps’ Life Sciences valuation advisory team walk you through a purchase price allocation for a hypothetical biotechnology company based on real world experience.
Key Insights
Panelists
Technology continues to impact the relationship between businesses and their stakeholders, with data exchange, digital service provision and innovation all driving discussion. Our panel of experts address data-driven approaches to patient care, the impact of technology on regulation, and IP, data privacy and cyber security issues in the healthcare and life sciences industry.
Key Insights
Panelists
Our panel of leading attorneys discuss current issues facing the life sciences industry with respect to the management, protection and enforcement of IP rights in the UK, Europe and the U.S.
Key Insights
Panelists
Chris Campbell, Chief Strategist at Kroll, Michael Kiely, President of U.S. Government Affairs at UPS and John Selib, Senior Vice President, Global Policy & Public Affairs at Pfizer, sat down for a fireside chat on the impact of regulation on the life sciences industry as well as emerging hot topics.
Key Insights
Panelists
This discussion provides insights on how the post-COVID-19 environment is challenging for the pharmaceutical and medical device industries. The increased public scrutiny and rapid development of and changes to these industries over the past year amplifies existing operational risks. Our panel of experts addressed evolving risks challenging life sciences global supply chains, including around price gouging rules, how to identify risk exposure and navigate the complex regulatory landscape.
Key Insights
Panelists
Valuation of businesses, assets and alternative investments for financial reporting, tax and other purposes.
Middle Market M&A, Strategic Advisory, Debt Advisory and Private Capital Markets, Restructuring and Insolvency Services, Financial Due Diligence, Fairness Opinions, Solvency Opinions and ESOP/ERISA Advisory.
The Kroll Investigations, Diligence and Compliance team partners with clients to anticipate, detect and manage regulatory and reputational risks associated with global ethics and compliance obligations.
The Kroll Investigations, Diligence and Compliance team consists of experts in forensic investigations and intelligence, delivering actionable data and insights that help clients worldwide make critical decisions and mitigate risk.
Seamless analytical advisory through the deal continuum, from transaction origination to closing.
Incident response, digital forensics, breach notification, security strategy, managed security services, discovery solutions, security transformation.
Kroll’s Enterprise Security Risk Management practice provides expert guidance and advisory services to our global clientele as they navigate the most challenging and emerging security and threat-related issues.
End-to-end governance, advisory and monitorship solutions to detect, mitigate, drive efficiencies and remediate operational, legal, compliance and regulatory risk.
Independent expert analysis, testimony, advice and investigations for complex disputes and projects.
by Joshua Tucker
by Thomas Bock, Fernanda Barroso, David Lewis
